The NEOMED Institute attracts, creates, and leads a network of small and medium enterprises (SMEs) to take charge of what pharma companies were doing in the discovery of new drugs, and to bridge the gap between academic innovation and industry needs.
The NEOMED Institute is a response to the changing pharma R&D business model. In view of the considerable gap between basic research and the commercialization of new drugs, we seek to create a bridge.
We provide industrial expertise in drug discovery and development combined with funding and a favourable ecosystem to transform innovations into solid therapeutic solutions. We drive drug discovery activities up to the stage of human proof of concept. This stage is an important turning point, where projects become attractive to the biopharmaceutical industry or can constitute the basis for the creation of solid start-up companies.
We have two fully integrated research and development facilities: one in Technoparc Montréal’s Saint-Laurent Campus, specializing in small molecule therapeutics, and the other facility, specializing in the development of biologics and vaccines, is located in Laval. Both facilities function as open-access drug discovery hubs housing independent commercial businesses and providing a dynamic environment that stimulates collaboration, innovation, and creativity.
The NEOMED Institute is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada.